Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.

Industry: Biological Products, (No Diagnostic Substances) Peers: Alpha Teknova Inc BNB Plus Corp Champions Oncology Inc Niagen Bioscience Inc Telesis Bio Inc. Standard BioTools Inc Harvard Bioscience Inc RADNOSTIX, INC. IsoPlexis Corp Thermo Fisher Scientific Inc